• Behavioral Health
  • Clinical Insights
  • Treatment

Why medication-assisted treatment is essential for improving patient outcomes

Mar 6th, 2023

3 ways your patients can benefit from medication assisted treatment

According to Substance Abuse and Mental Health Services Administration (SAMHSA), medication-assisted treatment (MAT) is a term used to describe the use of medication, along with other support mechanisms, to treat opioid, tobacco or alcohol use disorder. While the overall goal of MAT is full recovery, success in outcomes can be measured in other ways, such as a patient’s ability to gain and maintain employment; display consistency in a treatment regimen; and an improvement in patient survival for those living with opioid use disorder.

  1. Increases treatment and medication adherence

    A specialized treatment program, such as an inpatient behavioral health service, is not necessary for patients using medication-assisted treatment. MAT in the primary care setting makes treatment more accessible for patients living with substance use disorders and improves medication adherence in over two-thirds of patients1.

  2. Decreases illicit opioid use and overdoses

    The NIH found that for those receiving MAT services, specifically those treated with the FDA-approved medication methadone, opioid overdose deaths decreased by 59 percent. Patients prescribed buprenorphine, another FDA-approved medication used in MAT programs, experienced a decrease in overdose deaths by 38 percent2.

  3. Overall improvement of public health

    The integration of MAT and primary care represents an opportunity for patients to receive treatment for both substance use disorder and other co-occurring health issues in one location. A study shows that an integrated care model where MAT services are provided alongside primary care helps to minimize the stigma and discrimination associated with drug treatment services while improving overall health outcomes.3

Ready to learn more?

Curious about how medication-assisted treatment can help support your consumers? Genoa can help. Contact us today and we’ll be in touch.

"*" indicates required fields

Name*
Does your organization currently partner with Genoa?*
This field is for validation purposes and should be left unchanged.

Recent Posts


  • Behavioral Health
  • Clinical Insights
  • Treatment
4 things to know about Spravato® (Intranasal esketamine)

On January 21, 2025, the FDA announced the approval of Spravato® nasal spray as a monotherapy treatment for treatment-resistant depression (TRD), making this medication the first and only monotherapy option...

  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa’s 2024 Art Celebration: Celebrating the healing power of creativity

“I’ve always expressed myself through my art and learned to use my creativity to inspire others”, says Genoa Healthcare 2024 Art Celebration participant Shanelle G. Genoa’s annual Art Celebration invites...

Partner with Genoa
  • Behavioral Health
  • Clinical Insights
  • Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression

Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...

  • Behavioral Health
  • Clinical Insights
  • Partnering with Genoa
CMS reporting now required: 4 ways Genoa can help

By Reena Neumann, PharmD, MBA Since January 1, 2024, the Centers for Medicare & Medicaid Services (CMS) has required that clinics provide outcomes data reporting to secure federal funding through...